Retatrutide
Phase 3aka LY3437943
Triple agonist (GLP-1, GIP, glucagon) in phase 3 for obesity. The one everyone's watching.
Mechanism
One molecule hitting three metabolic receptors at once: GLP-1, GIP, and glucagon. The glucagon arm is the interesting part, it bumps energy expenditure on top of the appetite suppression you already get from a GLP-1. On paper it should out-cut tirzepatide, and the phase 2 numbers backed that up.
Regulatory & Safety Status
Still investigational. Lilly's compound, no regulator has signed off, so everything you read is trial data. Anything sold to you right now is grey market.
Research
Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs
Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome
Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis
Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats
Retatrutide phase 2 obesity trial
Phase 2 RCT reporting dose-dependent weight reduction over 48 weeks.
Latest retatrutide research